RSS   Newsletter   Contact   Advertise with us
Post Online Media

Motif Bio appoints Robert Dickey as CFO

Motif BioMotif Bio plc (Motif), a clinical stage biopharmaceutical company, announces that Robert Dickey IV has been appointed as chief financial officer.
Article continues below

READ MORE NeoStem names new CFO

Mr. Dickey is an accomplished financial professional with senior leadership experience in private and public healthcare companies.

Prior to joining Motif Bio, Mr. Dickey was CFO at Tyme Technologies Inc., a NASDAQ-listed clinical stage oncology company.

He previously held senior leadership positions at NeoStem, Inc. (now known as Caladrius Biosciences Inc.), Hemispherx Biopharma Inc., Stemcyte Inc., Locus Pharmaceuticals Inc. and Protarga Inc.

Mr. Dickey began his career as an Investment Banker at Lehman Brothers and Legg Mason Wood Walker Inc.

Pete Meyers is leaving Motif Bio and has agreed to transition the CFO responsibilities to Mr. Dickey over the course of the next several weeks.



We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy